Current treatment of low grade astrocytoma: A review

Clinical Neurology and Neurosurgery

Volumn 115, Issue 1, 2013, Pages 1-8

  Pedersen, Christina Louise ^a   Romner, Bertil ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chemotherapy; Clinical biomarkers; Low grade astrocytoma; Radiotherapy; Review; Surgical treatment

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; VASCULOTROPIN; VIMENTIN; VINCRISTINE;

AGE; ASTROCYTOMA; ATAXIA; BALANCE DISORDER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DISEASE ASSOCIATION; DNA METHYLATION; FOCAL EPILEPSY; GAMMA KNIFE RADIOSURGERY; GENE MUTATION; HEADACHE; HISTOPATHOLOGY; HUMAN; HYDROCEPHALUS; KARNOFSKY PERFORMANCE STATUS; LOW GRADE ASTROCYTOMA; NEUROFIBROMATOSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARALYSIS; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; REVIEW; SENSORY DYSFUNCTION; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZED INCIDENCE RATIO; SYSTEMATIC REVIEW; TONIC CLONIC SEIZURE; TUBEROUS SCLEROSIS; TUMOR BIOPSY; WEAKNESS;

ASTROCYTOMA; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM GRADING; PROGNOSIS;

EID: 84870485164     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2012.07.002     Document Type: Review

References (58)

1. D.N. Louis WHO classification of tumours of the central nervous system Acta Neuropathologica 114 August (2) 2007 97 109
2. H. Duffau, and L. Capelle Preferential brain locations of low-grade gliomas Cancer 100 June (12) 2004 2622 2626
3. N. Sanai, S. Chang, and M.S. Berger Low-grade gliomas in adults Journal of Neurosurgery 115 November (5) 2011 948 965
4. M.L. Bondy, M.E. Scheurer, B. Malmer, J.S. Barnholtz-Sloan, F.G. Davis, and D. Il'yasova Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium Cancer 113 October (7 Suppl.) 2008 1953 1968
5. Jallo GI, Benardete EA. Low-grade astrocytoma. 1-8-2010. Ref type: online source.
6. J. Pallud, L. Capelle, L. Taillandier, D. Fontaine, E. Mandonnet, and R. Guillevin Prognostic significance of imaging contrast enhancement for WHO grade II gliomas Neuro-oncology 11 April (2) 2009 176 182
7. J. Ruiz, and G.J. Lesser Low-grade gliomas Current Treatment Options in Oncology 10 August (3-4) 2009 231 242
8. Z. Lwin, H.K. Gan, and W.P. Mason Low-grade oligodendroglioma: current treatments and future hopes Expert Review of Anticancer Therapy 9 November (11) 2009 1651 1661
9. A. Hlobilkova, J. Ehrmann, P. Knizetova, V. Krejci, O. Kalita, and Z. Kolar Analysis of VEGF, Flt-1 Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression Neoplasma 56 4 2009 284 290
10. G. Bauman, B. Fisher, C. Watling, J.G. Cairncross, and D. Macdonald Adult supratentorial low-grade glioma: long-term experience at a single institution International Journal of Radiation Oncology, Biology, Physics 75 December (5) 2009 1401 1407
11. R. Durmaz, M. Vural, E. Isildi, E. Cosan, E. Ozkara, and C. Bal Efficacy of prognostic factors on survival in patients with low grade glioma Turkish Neurosurgery 18 October (4) 2008 336 344
12. F. Pignatti, M. van den Bent, D. Curran, C. Debruyne, R. Sylvester, and P. Therasse Prognostic factors for survival in adult patients with cerebral low-grade glioma Journal of Clinical Oncology 20 April (8) 2002 2076 2084
13. E.F. Chang, A. Clark, R.L. Jensen, M. Bernstein, A. Guha, and G. Carrabba Multiinstitutional validation of the University of California at San Francisco low-grade glioma prognostic scoring system clinical article Journal of Neurosurgery 111 August (2) 2009 203 210
14. R. Helseth, E. Helseth, T.B. Johannesen, C.W. Langberg, K. Lote, and P. Ronning Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme Acta Neurologica Scandinavica 122 September (3) 2010 159 167
15. L. Bissola, M. Eoli, B. Pollo, B.M. Merciai, A. Silvani, and E. Salsano Association of chromosome 10 losses and negative prognosis in oligoastrocytomas Annals of Neurology 52 December (6) 2002 842 845
16. M. Kujas, J. Lejeune, A. Benouaich-Amiel, E. Criniere, F. Laigle-Donadey, and Y. Marie Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas Annals of Neurology 58 August (2) 2005 322 326
17. J.S. Smith, A. Perry, T.J. Borell, H.K. Lee, J. O'Fallon, and S.M. Hosek Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas Journal of Clinical Oncology 18 February (3) 2000 636 645
18. M. Weller, H. Berger, C. Hartmann, J. Schramm, M. Westphal, and M. Simon Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clinical Cancer Research 13 December (23) 2007 6933 6937
19. A.R. Fathi, E. Vassella, M. Arnold, J. Curschmann, M. Reinert, and I. Vajtai Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status Strahlentherapie und Onkologie 183 September (9) 2007 517 522
20. F.S. Pardo, D.W. Hsu, R. Zeheb, J.T. Efird, P.G. Okunieff, and D.M. Malkin Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage British Journal of Cancer 91 November (9) 2004 1678 1686
21. M. Stander, A. Peraud, B. Leroch, and F.W. Kreth Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis Cancer 101 September (5) 2004 1028 1035
22. S. Everhard, G. Kaloshi, E. Criniere, A. Benouaich-Amiel, J. Lejeune, and Y. Marie MGMT methylation: a marker of response to temozolomide in low-grade gliomas Annals of Neurology 60 December (6) 2006 740 743
23. 6- methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas Brain Pathology 13 April (2) 2003 176 184
24. 6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma Surgical Neurology 68 December (6) 2007 603 608
25. M.J. McGirt, K.L. Chaichana, F.J. Attenello, J.D. Weingart, K. Than, and P.C. Burger Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas Neurosurgery 63 October (4) 2008 700 707
26. J.S. Smith, E.F. Chang, K.R. Lamborn, S.M. Chang, M.D. Prados, and S. Cha Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas Journal of Clinical Oncology 26 March (8) 2008 1338 1345
27. E.G. Shaw, B. Berkey, S.W. Coons, D. Bullard, D. Brachman, and J.C. Buckner Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial Journal of Neurosurgery 109 November (5) 2008 835 841
28. R. Ahmadi, C. Dictus, C. Hartmann, O. Zurn, L. Edler, and M. Hartmann Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients Acta Neurochirurgica 151 November (11) 2009 1359 1365
29. T. Kilic, K. Ozduman, I. Elmaci, A. Sav, and P.M. Necmettin Effect of surgery on tumor progression and malignant degeneration in hemispheric diffuse low-grade astrocytomas Journal of Clinical Neuroscience 9 September (5) 2002 549 552
30. H. Duffau The challenge to remove diffuse low-grade gliomas while preserving brain functions Acta Neurochirurgica 154 April (4) 2012 569 574
31. Y.N. Yordanova, S. Moritz-Gasser, and H. Duffau Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection Clinical article Journal of Neurosurgery 115 August (2) 2011 232 239
32. L. Mariani, P. Siegenthaler, R. Guzman, D. Friedrich, A.R. Fathi, and C. Ozdoba The impact of tumour volume and surgery on the outcome of adults with supratentorial WHO grade II astrocytomas and oligoastrocytomas Acta Neurochirurgica 146 May (5) 2004 441 448
33. H. Duffau, L. Taillandier, and L. Capelle Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma Journal of Neuro-Oncology 80 November (2) 2006 171 176
34. L.W. Wang, C.Y. Shiau, W.Y. Chung, H.M. Wu, W.Y. Guo, and K.D. Liu Gamma Knife surgery for low-grade astrocytomas: evaluation of long-term outcome based on a 10-year experience Journal of Neurosurgery 105 December (Suppl.) 2006 127 132
35. C.G. Hadjipanayis, A. Niranjan, E. Tyler-Kabara, D. Kondziolka, J.C. Flickinger, and L.D. Lunsford Stereotactic radiosurgery for well-circumscribed fibrillary grade II astrocytomas: an initial experience Stereotactic and Functional Neurosurgery 79 1 2002 13 24
36. M.J. van den Bent, D. Afra, W.O. De, H.M. Ben, S. Schraub, and K. Hoang-Xuan Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial Lancet 366 September (9490) 2005 985 990
37. Z. Hanzely, C. Polgar, J. Fodor, J.M. Brucher, D. Vitanovics, and L.C. Mangel Role of early radiotherapy in the treatment of supratentorial WHO Grade II astrocytomas: long-term results of 97 patients Journal of Neuro-Oncology 63 July (3) 2003 305 312
38. C. Leighton, B. Fisher, D. Macdonald, L. Stitt, G. Bauman, and J. Cairncross The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection Journal of Neuro-Oncology 82 April (2) 2007 165 170
39. K. Skold, B. Stenstam, A.Z. Diaz, V. Giusti, L. Pellettieri, and J.W. Hopewell Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f Acta Neurologica Scandinavica 122 July (1) 2010 58 62
40. Y. Nakagawa, and H. Hatanaka Boron neutron capture therapy. Clinical brain tumor studies Journal of Neuro-Oncology 33 May (1-2) 1997 105 115
41. W. Taal, H.J. Dubbink, C.B. Zonnenberg, B.A. Zonnenberg, T.J. Postma, and J.M. Gijtenbeek First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response Neuro-oncology 13 February (2) 2011 235 241
42. A. Pace, A. Vidiri, E. Galie, M. Carosi, S. Telera, and A.M. Cianciulli Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response Annals of Oncology 14 December (12) 2003 1722 1726
43. G. Kaloshi, A. Benouaich-Amiel, F. Diakite, S. Taillibert, J. Lejeune, and F. Laigle-Donadey Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome Neurology 68 May (21) 2007 1831 1836
44. E.M. Stege, J.M. Kros, H.G. de Bruin, R.H. Enting, H. van, and I.L.H. Looijenga Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine Cancer 103 February (4) 2005 802 809
45. J.C. Buckner, D. Gesme Jr., J.R. O'Fallon, J.E. Hammack, S. Stafford, and P.D. Brown Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities Journal of Clinical Oncology 21 January (2) 2003 251 255
46. M. Henze, A. Mohammed, H.P. Schlemmer, K.K. Herfarth, S. Hoffner, and S. Haufe PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis Journal of Nuclear Medicine 45 April (4) 2004 579 586
47. 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value European Journal of Nuclear Medicine and Molecular Imaging 32 January (1) 2005 39 51
48. 3 PET Journal of Neuro-Oncology 82 May (3) 2007 305 311
49. 1H MR spectroscopic imaging for increasing diagnostic accuracy Neuroradiology 47 November (11) 2005 826 834
50. W.S. Song, L.B. Guo, Z.Y. Hong, J.J. Li, and J. Wu Serum S100 protein and radiation-induced brain injury in astrocytoma patients Di Yi Jun Yi Da Xue Xue Bao 25 June (6) 2005 723 725
51. M. Landriscina, G. Schinzari, L.G. Di, M. Quirino, A. Cassano, and E. D'Argento S100A13, a new marker of angiogenesis in human astrocytic gliomas Journal of Neuro-Oncology 80 December (3) 2006 251 259
52. D. Ribom, J. Andrae, M. Frielingsdorf, M. Hartman, M. Nister, and A. Smits Prognostic value of platelet derived growth factor alpha receptor expression in grade 2 astrocytomas and oligoastrocytomas Journal of Neurology, Neurosurgery and Psychiatry 72 June (6) 2002 782 787
53. J. Li, H.Y. Guan, L.Y. Gong, L.B. Song, N. Zhang, and J. Wu Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival Clinical Cancer Research 14 November (21) 2008 6996 7003
54. N. Sanai, and M.S. Berger Glioma extent of resection and its impact on patient outcome Neurosurgery 62 April (4) 2008 753 764
55. F.G. Dhermain, P. Hau, H. Lanfermann, A.H. Jacobs, and M.J. van den Bent Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas Lancet Neurology 9 September (9) 2010 906 920
56. S. Rorive, X.M. Lopez, C. Maris, A.L. Trepant, S. Sauvage, and N. Sadeghi TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas Modern Pathology 23 October (10) 2010 1418 1428
57. O. Arrieta, B. Pineda-Olvera, P. Guevara-Salazar, N. Hernandez-Pedro, D. Morales-Espinosa, and T.L. Ceron-Lizarraga Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis British Journal of Cancer 99 July (1) 2008 160 166
58. H. Yoo, S. Sohn, B.H. Nam, H.S. Min, E. Jung, and S.H. Shin The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis International Journal of Molecular Medicine 26 July (1) 2010 3 9